Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis

Benzer Materyaller

• Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
  Yazar:: Taylor, P, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
  Yazar:: Weinblatt, M, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
  Yazar:: Weinblatt, M, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
  Yazar:: Taylor, P, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
  Yazar:: Gerd Burmester, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-02-01)